Unity Biotechnology, Inc. (0YC0.L)
USD 0.94
(3.99%)
USD 0.94
(3.99%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 65.69 Million USD | -47.17% |
| 2022 | 124.35 Million USD | -0.29% |
| 2021 | 124.71 Million USD | -20.22% |
| 2020 | 156.31 Million USD | 3.37% |
| 2019 | 151.22 Million USD | -16.63% |
| 2018 | 181.37 Million USD | 77.78% |
| 2017 | 102.02 Million USD | 5.56% |
| 2016 | 96.64 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 58.86 Million USD | -10.39% |
| 2024 Q3 | 47.13 Million USD | -11.94% |
| 2024 Q2 | 53.52 Million USD | -9.07% |
| 2023 Q4 | 65.69 Million USD | -5.17% |
| 2023 Q1 | 114.25 Million USD | -8.12% |
| 2023 FY | 65.69 Million USD | -47.17% |
| 2023 Q2 | 101 Million USD | -11.59% |
| 2023 Q3 | 69.27 Million USD | -31.42% |
| 2022 Q1 | 112.46 Million USD | -9.82% |
| 2022 FY | 124.35 Million USD | -0.29% |
| 2022 Q4 | 124.35 Million USD | -8.83% |
| 2022 Q3 | 136.39 Million USD | 39.76% |
| 2022 Q2 | 97.59 Million USD | -13.23% |
| 2021 Q1 | 148.18 Million USD | -5.2% |
| 2021 Q4 | 124.71 Million USD | -0.78% |
| 2021 Q2 | 136.26 Million USD | -8.05% |
| 2021 FY | 124.71 Million USD | -20.22% |
| 2021 Q3 | 125.69 Million USD | -7.76% |
| 2020 FY | 156.31 Million USD | 3.37% |
| 2020 Q2 | 164.69 Million USD | 4.38% |
| 2020 Q1 | 157.78 Million USD | 4.34% |
| 2020 Q3 | 174.97 Million USD | 6.24% |
| 2020 Q4 | 156.31 Million USD | -10.66% |
| 2019 FY | 151.22 Million USD | -16.63% |
| 2019 Q4 | 151.22 Million USD | 6.74% |
| 2019 Q3 | 141.67 Million USD | -8.13% |
| 2019 Q2 | 154.21 Million USD | -4.1% |
| 2019 Q1 | 160.79 Million USD | -11.35% |
| 2018 Q1 | 144.1 Million USD | 41.24% |
| 2018 FY | 181.37 Million USD | 77.78% |
| 2018 Q4 | 181.37 Million USD | -6.85% |
| 2018 Q3 | 194.72 Million USD | -6.59% |
| 2018 Q2 | 208.45 Million USD | 44.66% |
| 2017 FY | 102.02 Million USD | 5.56% |
| 2017 Q4 | 102.02 Million USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 FY | 96.64 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 92.102% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 92.99% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 91.555% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 60.309% |
| bluebird bio, Inc. | 619.16 Million USD | 89.39% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 47.8% |
| Imunon, Inc. | 21.91 Million USD | -199.707% |
| Editas Medicine, Inc. | 499.15 Million USD | 86.84% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.754% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 98.042% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 94.52% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 97.98% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 95.338% |
| Verastem, Inc. | 149.71 Million USD | 56.124% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.919% |
| Waters Corporation | 4.62 Billion USD | 98.58% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.933% |
| Biogen Inc. | 26.84 Billion USD | 99.755% |
| Nektar Therapeutics | 398.03 Million USD | 83.496% |
| Perrigo Company plc | 10.8 Billion USD | 99.392% |
| Dynavax Technologies Corporation | 997.09 Million USD | 93.412% |
| Illumina, Inc. | 10.11 Billion USD | 99.35% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -132.347% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 91.582% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 70.477% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.04% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 60.265% |
| Evolus, Inc. | 188.99 Million USD | 65.243% |
| Adicet Bio, Inc. | 207.29 Million USD | 68.311% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 66.723% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.801% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 68.08% |
| FibroGen, Inc. | 423.52 Million USD | 84.49% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 99.39% |
| OPKO Health, Inc. | 2.01 Billion USD | 96.735% |
| Homology Medicines, Inc. | 47.05 Million USD | -39.597% |
| Geron Corporation | 394.07 Million USD | 83.331% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 98.285% |
| Exelixis, Inc. | 2.94 Billion USD | 97.767% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 82.173% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 57.451% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 94.951% |
| Zoetis Inc. | 14.28 Billion USD | 99.54% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 88.833% |
| Abeona Therapeutics Inc. | 64 Million USD | -2.637% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.711% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -17.41% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 97.803% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 97.988% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 89.431% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 96.21% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 93.739% |
| Insmed Incorporated | 1.32 Billion USD | 95.06% |
| TG Therapeutics, Inc. | 329.58 Million USD | 80.069% |
| Incyte Corporation | 6.78 Billion USD | 99.031% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 96.42% |